• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study shows sustained improvements with Medtronic’s MiniMed 780G with Guardian 4

April 27, 2022 By Sean Whooley

Medtronic MiniMed 780G
The Medtronic MiniMed 780G system. [Image from Medtronic]
Medtronic (NYSE:MDT) announced today that the extended study phase of its MiniMed 780G insulin pump system produced positive data.

Fridley, Minnesota-based Medtronic presented new data from the study of MiniMed 780G with the no-calibration, non-adjunctive Guardian 4 sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona.

Data demonstrated sustained improvements in glycemic outcomes that met or exceeded consensus guideline recommendations of 70% time in range with less user interaction and fewer fingerstick calibrations, according to a news release.

Time in range registered at 72.8%, with adults averaging 76.3% and children between seven and 17 years old averaging 70.7%. No episodes of diabetic ketoacidosis (DKA) or severe hypoglycemia occurred, while the average time spent in advanced hybrid closed loop mode came in at more than 90% across all age groups.

Medtronic began the pivotal study of the advanced hybrid closed loop (AHCL) system in 2019 and the study concluded in 2021, at which point participants were offered the opportunity to stay on the product as part of the extended study phase. The extension covers 176 participants aged between seven and 75 years old.

Study participants did not have to calibrate their sensor at a minimum of twice per day due to the transition from the previous generation Guardian 3 sensor to the next-generation Guardian 4. Even with fewer calibrations, participants achieved glycemic targets similar to those observed in the trial of the AHCL system with Guardian 3, Medtronic said.

MiniMed 780G with Guardian 4 is available in more than 40 countries and is under review by the FDA for U.S. approval. However, earlier this year, CEO Geoff Martha said there was some uncertainty over approval timing for Medtronic’s next-generation platforms, including the MiniMed 780G insulin pump and Guardian 4 CGM sensor, as a result of a December 2021, FDA warning letter highlighting inadequacies in specific medical device quality system requirements at its diabetes business’ Northridge, California, facility.

Filed Under: Auto-injectors, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS